Keywords: Bayer, R&D pipeline, Xarelto, Thrombosis, Alpharadin, cancer, Regorafenib, Eylea, AMD

Bayer boasts four potential pipeline blockbusters

Article | 21 December 2011

Print This

German drugs and crop and material sciences group Bayer (BAT: DE) said yesterday that it plans to continue investing heavily ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in